Cor Vasa 2021, 63(3):304-311 | DOI: 10.33678/cor.2021.058

CHA2DS2-VASc and HAS-BLED scores are not associated with cardiac defibrillators therapies

Yakup Alsancak, Hasan Sari, Ahmet Seyfeddin Gurbuz, Ahmet Lutfi Sertdemir, Alpay Aribas, Ahmet Soylu
Necmettin Erbakan University, Meram Medical Faculty Department of Cardiology, Konya, Turkey

Aim: The CHA2DS2-VASc (heart failure, hypertension, age >75, diabetes mellitus, stroke history, vascular disease, 65-74 age range, gender) and HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleed- ing history, labile INR, elderly, drugs/alcohol) are scoring system for using to estimate stroke and bleeding development in cases with atrial fibrillation. We aim to evaluate the relationship between the implantable cardioverter defibrillator (ICD) therapies and CHA2DS2-VASc and HAS-BLED scores.

Methods: 398 patients were included in this retrospective study after reviewing the data of the patients above the age of 18 who had ICD implantation for any reason between 2014-2019 and who were found to have at least two pacemaker check-ups with 6-month intervals. CHA2DS2-VASc and HAS-BLED scores were calculated during the device implantation and last control visit date.

Results: 148 of the patients received ICD therapy (appropriate shock [n = 118] and in appropriate therapy [n = 30]) and 250 of them did not receive any therapy. It was observed that the CHA2DS2-VASc and HAS-BLED scores were similar in the groups receiving and not receiving therapy (respectively, p = 0.64 and p = 0.60). CHA2DS2-VASc and HAS-BLED scores were similar in patients with appropriate shock or not (respectively, p = 0.89 and p = 0.85) with median follow-up period 5.5 years. Multivariate regression analysis showed that reduced ejection fraction, presence of single-chamber ICD, lapsing of a long time after the implantation were independent risk factors for ICD device therapies (p < 0.05).

Conclusions: CHA2DS2-VASc and HAS-BLED scores are not associated with device-based ICD therapies.

Keywords: CHA2DS2-VASc, HAS-BLED, ICD, Shock, Therapy

Received: July 19, 2020; Revised: July 19, 2020; Accepted: April 27, 2021; Published: July 20, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Alsancak Y, Sari H, Seyfeddin Gurbuz A, Lutfi Sertdemir A, Aribas A, Soylu A. CHA2DS2-VASc and HAS-BLED scores are not associated with cardiac defibrillators therapies. Cor Vasa. 2021;63(3):304-311. doi: 10.33678/cor.2021.058.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016;18:1609-1678. Go to original source... Go to PubMed...
    2. Temizer O, Açar B, Yayla Ç, et al. The Association between CHA2DS2-VASc Score and Mortality in Patients with Heart Failure with Reduced Ejection Fraction. Acta Cardiol Sin 2017;33:429-435.
    3. Onuk T, Karataş MB, İpek G, et al. Higher CHA2DS2-VASc Score Is Associated With Increased Mortality in Acute Pulmonary Embolism. Clin Appl Thromb Hemost 2017;23:631-637. Go to original source... Go to PubMed...
    4. Ipek G, Onuk T, Karatas MB, et al. CHA2DS2-VASc score is a predictor of no-reflow in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous intervention. Angiology 2016;67:840-845. Go to original source... Go to PubMed...
    5. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-1940. Go to original source... Go to PubMed...
    6. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Europace 2015;17:1601-1687. Go to PubMed...
    7. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 2018;138:272-391. Go to original source... Go to PubMed...
    8. Wilkoff BL, Hess M, Young J, et al. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. J Cardiovasc Electrophysiol 2004;15:1002-1009. Go to original source... Go to PubMed...
    9. Konstantino Y, Shafat T, Novack V, et al. Incidence of Implantable Cardioverter Defibrillator Therapy and Mortality in Primary and Secondary Prevention of Sudden Cardiac Death. Isr Med Assoc J 2015;17:760-763. Go to PubMed...
    10. van Rees JB, Borleffs CJ, de Bie MK, et al. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J Am Coll Cardiol 2011;57:556-562. Go to original source... Go to PubMed...
    11. Yang JH, Byeon K, Yim HR, et al. Predictors and Clinical Impact of Inappropriate Implantable Cardioverter-Defibrillator Shocks in Korean Patients. J Korean Med Sci 2012;27:619-624. Go to original source... Go to PubMed...
    12. Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010;137:263-273. Go to original source... Go to PubMed...
    13. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The Task Force for theManagement of Atrial Fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA). Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010;31:2369-2429.
    14. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics implantable defibrillator study. Cardiac arrest study Hamburg. Canadian implantable defibrillator study. Eur Heart J 2000;21:2071-2078. Go to original source... Go to PubMed...
    15. Goldenberg I, Vyas AK, Hall WJ, et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008;51:288-296. Go to original source... Go to PubMed...
    16. Gradaus R, Block M, Brachmann J, et al. Mortality, morbidity, and complications in 3344 patients with ICDS: Results from the German ICD Registry EURID. PACE 2003;26:1511-1518. Go to original source... Go to PubMed...
    17. Schron EB, Exner DV, Yao Q, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: Impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 2002;105:589-594. Go to original source... Go to PubMed...
    18. Tzeis S, Kolb C, Baumert J, et al. Effect of depression on mortality in implantable cardioverter defibrillator recipients - Findings from the prospective LICAD study. Pacing Clin Electrophysiol 2011;34:991-997. Go to original source... Go to PubMed...
    19. Sood N, Ruwald AC, Solomon S, et al. Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT. Eur Heart J 2014;35:106-115. Go to original source... Go to PubMed...
    20. Qian Z, Zhang Z, Guo J, et al. Association of implantable cardioverter defibrillator therapy with all-cause mortality - a systematic review and meta-analysis. Pacing Clin Electrophysiol 2016;39:81-88. Go to original source... Go to PubMed...
    21. Menon V, Steinberg JS, Akiyama T, et al. Implantable cardioverter defibrillator discharge rates in patients with unexplained syncope, structural heart disease, and inducible ventricular tachycardia at electrophysiologic study. Clin Cardiol 2000;23:195-200. Go to original source... Go to PubMed...
    22. Hreybe H, Bedi M, Ezzeddine R, et al. Indications for internal cardioverter defibrillator implantation predict time to first shock and the modulating effect of β blockers. Am Heart J 2005;150:1064.e1-1064.e5. Go to original source... Go to PubMed...
    23. Hreybe H, Ezzeddine R, Bedi M, et al. Renal insufficiency predicts the time to first appropriate defibrillator shock. Am Heart J 2006;151:852-856. Go to original source... Go to PubMed...
    24. Whang W, Albert CM, Sears SF, et al. Depression as a predictor for appropriate shocks among patients with implantable cardioverter defibrillators. J Am Coll Cardiol 2005;45:1090-1105. Go to original source... Go to PubMed...
    25. Sanchez JM, Greenberg SL, Chen J, et al. Smokers are at markedly increased risk of appropriate defibrillator shocks in a primary prevention population. Heart Rhythm 2006;3:443-449. Go to original source... Go to PubMed...
    26. Nanthakumar K, Dorian P, Paquette M, et al. Is inappropriate implantable defibrillator shock therapy predictable? J Interventional Cardiac Electrophysiol 2003;8:215-220. Go to original source... Go to PubMed...
    27. Zhang Y, Guallar E, Colmenares BE, et al. Changes in Follow-up Left Ventricular Ejection Fraction Associated with Outcomes in Primary Prevention ICD and CRT-D Recipients. J Am Coll Cardiol 2015;66:524-531. Go to original source... Go to PubMed...
    28. Yildirir A, Batur MK, Oto A. Hypertension and arrhythmia: blood pressure control and beyond. Europace 2002;4:175-182. Go to original source... Go to PubMed...
    29. Verma A, Sarak B, Kaplan AJ, et al. Predictors of appropriate implantable cardioverter defibrillator (ICD) therapy in primary prevention patients with ischemic and nonischemic cardiomyopathy. Pacing Clin Electrophysiol 2010;33:320-329. Go to original source... Go to PubMed...
    30. Morani G, Facchin D, Molon G, et al. Prediction of mortality in patients with implantable defibrillator using CHADS2 score: data from a prospective observational investigation. Am J Cardiovasc Dis 2018;8:48-57.
    31. Gunay S, Seyis S, Kurmus O. Benefit of CHA2DS2-VASc score in predicting implantable cardioverter defibrillator shocks. Cardiol Vasc Res 2018;2:1-5. Go to original source...
    32. Bergau L, Tichelbacker T, Kessel B, et al. Predictors of mortality and ICD shock therapy in primary prophylactic ICD patients - A systematic review and meta-analysis. PLoS ONE 2017;12:e0186387. Go to original source... Go to PubMed...
    33. Zaccardi F, Khan H, Laukkanen JA. Diabetes mellitus and risk of sudden cardiac death: a systematic review and meta-analysis. Int J Cardiol 2014;177:535-537. Go to original source... Go to PubMed...
    34. Lee DS, Hardy J, Yee R, et al. Clinical Risk Stratification for Primary Prevention Implantable Cardioverter Defibrillators CLINICAL PERSPECTIVE. Circ Heart Fail 2015;8:927-937. Go to original source... Go to PubMed...
    35. Ruwald MH, Zareba W, Jons C. Influence of diabetes mellitus on inappropriate and appropriate implantable cardioverter-defibrillator therapy and mortality in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) Trial. Circulation 2013;128:694-701. Go to original source... Go to PubMed...
    36. Tenma T, Yokoshiki H, Mizukami K, et al. Predictors and Proarrhythmic Consequences of Inappropriate Implantable Cardioverter-Defibrillator Therapy. Circ J 2015;79:1920-1927. Go to original source... Go to PubMed...
    37. Finsterer J, Wahbi K. CNS-disease affecting the heart: Brain-heart disorders. J Neurol Sci 2014;345:8-14. Go to original source... Go to PubMed...
    38. Sticherling C, Arendacka B, Svendsen JH, et al. Sex differences in outcomes of primary prevention implantable cardioverter-defibrillator therapy: combined registry data from eleven European countries. Europace 2018;20:963-970. Go to original source... Go to PubMed...
    39. Hong C, Alluri K, Shariff N, et al. Usefulness of the CHA2DS2-VASc Score to Predict Mortality in Defibrillator Recipients. Am J Cardiol 2017;120:83-86. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes